Yahoo · Sep 3, 2026
State Street Real Return ETF (RLY) Touches New 52-Week High
State Street Multi-Asset Real Return ETF hits a 52-week high as inflation concerns, easing policy expectations and real assets support gains.
RL
AMEX · RLY
SPDR SSgA Multi-Asset Real Return ETF
Financial Services · Asset Management
$36.27
Down-$0.04 (-0.11%)
Updated Nov 8, 2026, 1:56 PM
SID Score
4.2/10
Composite research score
Smart Money
—
Institutional and insider signal
- Market cap
- 645.9M
- P/E ratio
- —
- Dividend yield
- 2.18%
- 52-week range
- $34.23 – $38.38
- Volume
- 227.29K
- Avg. volume
- 68.6K
Price performance · RLY
RLY price history
1M range · 20 trading sessions · Daily adjusted prices
Prices through Nov 6, 2026
RLY closed at $36.27 after 20 trading sessions, down 2.13% for the selected period.
- Last close
- $36.27
- Period change
- -2.13%
- Period low
- $36.27
- Period high
- $37.41
Daily close
View OHLC price history
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Nov 6, 2026 | $35.96 | $36.38 | $35.96 | $36.27 | 227.29K |
| Nov 5, 2026 | $36.82 | $36.94 | $36.275 | $36.31 | 198K |
| Nov 4, 2026 | $37.00 | $37.00 | $36.55 | $36.63 | 183.54K |
| Nov 3, 2026 | $36.80 | $36.90 | $36.69 | $36.75 | 176.32K |
| Nov 2, 2026 | $37.32 | $37.32 | $36.94 | $36.94 | 302.96K |
| Oct 30, 2026 | $37.21 | $37.41 | $37.21 | $37.38 | 171.62K |
| Oct 29, 2026 | $37.14 | $37.38 | $37.14 | $37.38 | 172.75K |
| Oct 28, 2026 | $37.38 | $37.38 | $37.13 | $37.30 | 141.6K |
| Oct 27, 2026 | $37.16 | $37.32 | $37.16 | $37.27 | 234.68K |
| Oct 26, 2026 | $37.11 | $37.38 | $37.10 | $37.29 | 248.04K |
| Oct 23, 2026 | $37.07 | $37.4199 | $37.07 | $37.38 | 171.98K |
| Oct 22, 2026 | $37.38 | $37.38 | $36.885 | $37.13 | 129.52K |
| Oct 21, 2026 | $37.21 | $37.34 | $37.21 | $37.33 | 138.03K |
| Oct 20, 2026 | $37.15 | $37.31 | $37.1289 | $37.28 | 185.44K |
| Oct 19, 2026 | $37.24 | $37.3285 | $37.13 | $37.16 | 146.3K |
| Oct 16, 2026 | $37.10 | $37.42 | $37.10 | $37.41 | 89.9K |
| Oct 15, 2026 | $37.13 | $37.13 | $36.87 | $37.10 | 1.97M |
| Oct 14, 2026 | $37.05 | $37.11 | $36.93 | $37.08 | 253.58K |
| Oct 13, 2026 | $37.10 | $37.31 | $37.10 | $37.29 | 268.26K |
| Oct 12, 2026 | $37.03 | $37.08 | $36.93 | $37.06 | 268.7K |
Latest RLY news
The latest Smart Investors Daily articles mentioning RLY.
Stock researchCompany · Overview
Company
Market Activity
Research & News
RLY research
Overview
Company profile and research snapshot.
Company profile
Under normal circumstances, the Adviser invests at least 80% of the net assets of the fund among ETPs that provide exposure to the following primary asset classes: (i) inflation protected securities issued by the United States government; (ii) domestic and international real estate securities; (iii) commodities; (iv) publicly-traded domestic and international infrastructure companies; and (iv) publicly-traded companies in natural resources and/or commodities businesses.
Analyst outlook
Consensus and target data currently published for this company.
- Consensus
- —
- Average target
- —
- Implied upside
- —
- Analysts
- —
News briefing
No generated briefing is available yet.
globenewswire.com · Dec 12, 2025
Relay Therapeutics Announces Efficacy Subset Analysis of Zovegalisib (RLY-2608) + Fulvestrant in Breast Cancer Patients Pre-Treated with SERD or with ESR1 Mutations at SABCS 2025
Efficacy data remain consistent with previous disclosures, showing 10.3-month median PFS in all patients and 11.4-month median PFS in 2L patients Subset analyses show broad activity in patients with PI3Kα-mutated, HR+/HER2- metastatic breast cancer, regardless of prior fulvestrant or other SERD exposure, or ESR1 mutation status Phase 3 ReDiscover-2 trial in CDK4/6-experienced breast cancer ongoing CAMBRIDGE, Mass., Dec. 12, 2025 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage, small molecule precision medicine company developing potentially life-changing therapies for patients living with cancer and genetic disease, today announced a subset analysis of interim clinical data for zovegalisib (RLY-2608), the first known investigational allosteric, pan-mutant and isoform-selective inhibitor of PI3Kα.
defenseworld.net · Nov 30, 2025
SPDR SSgA Multi-Asset Real Return ETF (NYSEARCA:RLY) Reaches New 52-Week High – Should You Buy?
SPDR SSgA Multi-Asset Real Return ETF (NYSEARCA:RLY - Get Free Report) hit a new 52-week high during trading on Friday. The company traded as high as $31.76 and last traded at $31.7240, with a volume of 4621 shares trading hands. The stock had previously closed at $31.56. SPDR SSgA Multi-Asset Real Return ETF Trading
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
